ITG (Isotope Technologies Garching GmbH) is a subsidiary of ITM from Germany, being responsible for the development, production and logistics related to radioisotopes, besides the provision of services in medicine and industry areas. It manages the global network of ITM’s nuclear reactors, operating the radioisotopes production plants with radioactive material production license.
Its operating area is focused on Oncology, Personalized Medicine, Dermatology, Radiology, Cardiology. Lantheus is the global leader company in the development, manufacturing, sales and distribution of agents and products for image diagnosis. For more than 55 years it is dedicated to create and offer nuclear medicine solutions and to make available platforms that allow the progress of diagnosis and treatment of human diseases, Lantheus has more than 500 workers all over the world, headquartered in North Billerica, Massachusetts, United States, and offices in Puerto Rico, Canada and Australia. In Brazil, RPHGROUP is the exclusive representative for TechneLite® trading.
OncoBeta® GmbH is a private company specialized in the devolpment and trading of innovative and state-of-the-art therapies that use epidermal radioisotope applications such as Rhenium-SCT® (Non-Melanoma Skin Cancer Therapy). Headquartered in Munich, it is certified by the European CE and filled the approval regulatory request in other countries outside EU.
Global Medical Solutions it the leader in products and services for the global community of nuclear medicine and image diagnosis.
Telix is a global biopharmaceutical focused on the development of therapeutic and diagnose products based on directed radiopharmaceuticals or “Molecularly Targeted Radiation” (MTR).
The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP), and Indianapolis (US).
Telix is developing a cancer products’ portfolio in clinical stage that meet the medical needs that are not met in renal, prostate and brain (glioblastoma) cancers.